[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612895":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":30,"responsibleParty":58,"collaborators":61,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":77,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":92,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Eskisehir Osmangazi University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Premenopausal Women",null,"Women aged 40-60 years, premenopausal, diagnosed with major depressive disorder and\u002For generalized anxiety disorder, and currently receiving escitalopram treatment.",{"label":13,"type":10,"description":14,"interventionNames":10},"Postmenopausal Women","Women aged 40-60 years, postmenopausal, diagnosed with major depressive disorder and\u002For generalized anxiety disorder, and currently receiving escitalopram treatment.",[16],{"name":17,"affiliation":18,"role":19},"İmran G Yılmaz Karaman, Associtate Professor Doctor","Eskişehir Osmangazi University, Faculty of Medicine","PRINCIPAL_INVESTIGATOR",[21,27],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"İmran G Yılmaz Karaman, Associate Professor Doctor","CONTACT","02222392979","3600","imrangokcen.yilmazkaraman@ogu.edu.tr",{"name":28,"role":23,"phone":24,"phoneExt":25,"email":29},"Tuğçe Doğan, MD","dogaantugce@gmail.com",[31],{"facility":32,"status":10,"city":33,"state":10,"zip":34,"country":35,"countryCode":10,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Eskişehir Osmangazi University, Faculty of Medicine, Department of Psychiatry","Eskişehir","26040","Turkey (Türkiye)",{"type":37,"coordinates":38},"Point",[39,40],30.52056,39.77667,{"lat":40,"lon":39},[43,46,47,48,50,52,54,56],{"name":44,"role":23,"phone":45,"phoneExt":25,"email":26},"İmran G Yılmaz Karaman, Associate Professor","00902222392979",{"name":28,"role":23,"phone":45,"phoneExt":25,"email":29},{"name":44,"role":19,"phone":10,"phoneExt":10,"email":10},{"name":28,"role":49,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":51,"role":49,"phone":10,"phoneExt":10,"email":10},"Aybeniz Civan Kahve, Associate Professor",{"name":53,"role":49,"phone":10,"phoneExt":10,"email":10},"Sinem Kocagil, MD",{"name":55,"role":49,"phone":10,"phoneExt":10,"email":10},"Ali E Altınöz, Professor Doctor",{"name":57,"role":49,"phone":10,"phoneExt":10,"email":10},"Başar Sırmagül, Professor Doctor",{"type":19,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Imran Gokcen Yilmaz-Karaman","Associate professor doctor",[62],{"name":63,"class":6},"The Scientific and Technological Research Council of Turkey","100612895","escitalopram-plasma-concentrations-in-premenopausal-and-postmenopausal-women-100612895",false,"NCT07259525","Escitalopram Plasma Concentrations in Premenopausal and Postmenopausal Women","MENO-ES","Inclusion Criteria:\n\n* Aged 40 years or older and 60 years or younger\n* Diagnosed with major depressive disorder and\u002For generalized anxiety disorder by an independent psychiatrist (not a member of the research team)\n* Prescribed escitalopram treatment by an independent psychiatrist (not a member of the research team)\n* Receiving escitalopram treatment for at least one month and on a stable dose for at least one week\n* Willing to participate in the study and provide informed consent\n* Additional inclusion criterion for the menopausal group: Amenorrhea for at least one year (consistent with menopause diagnosis)\n* Additional inclusion criteria for the premenopausal group: Having regular menstrual cycles and being in the luteal phase (within 14 days after ovulation) of the menstrual cycle\n\nExclusion Criteria:\n\n* Diagnosis of intellectual disability, dementia, psychotic disorders, schizoaffective disorder, or bipolar disorder\n* Alcohol or substance use disorder\n* Diagnosis of hepatic failure, renal failure, or cardiac failure\n* Severe malnutrition\n* Presence of an active systemic infectious or inflammatory disease\n* Current use of hormone replacement therapy for menopause\n* Use of oral contraceptives\n* Pregnancy or breastfeeding\n* Use of medications known to affect escitalopram plasma concentration\n* Use of medications that affect the CYP2C19 enzyme\n* Detection of alleles other than the predominant CYP2C19\\*1 genotype in genetic analyses","FEMALE","40 Years","60 Years",{"count":75,"type":76},94,"ESTIMATED","14 Days","OBSERVATIONAL","This observational cross-sectional case-control study aims to evaluate the effects of menopausal status on escitalopram metabolism in women. The study will include premenopausal and menopausal women aged 40-60 years who are currently receiving escitalopram treatment and have applied to the Psychiatry Clinic of Eskişehir Osmangazi University. The study aims to identify pharmacokinetic differences associated with hormonal status and to investigate their potential clinical implications. Findings from this research are expected to contribute to the development of evidence-based, individualized treatment strategies for women in menopausal transition.",[81,82,83,84],"Therapeutic Drug Monitoring (TDM)","Menopause","Depression - Major Depressive Disorder","General Anxiety Disorder",[86,87,88,89,90,91],"escitalopram","desmethylescitalopram","menopause","therapeutic drug monitoring","major depressive disorder","general anxiety disorder","NOT_YET_RECRUITING","2025-12-16",{"date":95,"type":96},"2025-12-22","ACTUAL",{"date":98,"type":76},"2026-01",{"date":100,"type":76},"2028-06",{"name":5,"class":6},1]